These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 23953665)

  • 1. Clinical and health costs impact of progress in diagnosis and treatment in venous thromboembolic disease: evolution in 15 years.
    Vera-Arroyo B; Linares-Palomino JP; Lozano-Alonso S; Moreno-Villalonga JJ; Bravo-Molina A; Ros-Die E
    Ann Vasc Surg; 2013 Nov; 27(8):1162-8. PubMed ID: 23953665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients.
    Gussoni G; Foglia E; Frasson S; Casartelli L; Campanini M; Bonfanti M; Colombo F; Porazzi E; Ageno W; Vescovo G; Mazzone A;
    Thromb Res; 2013 Jan; 131(1):17-23. PubMed ID: 23141845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of diagnostic algorithms of deep vein thrombosis at the emergency department.
    Norlin JM; Elf JL; Svensson PJ; Carlsson KS
    Thromb Res; 2010 Sep; 126(3):195-9. PubMed ID: 20580416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
    Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
    Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
    Labas P; Ohrádka B; Vladimír J; Cambal M
    Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
    Wilbur K; Lynd LD; Sadatsafavi M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
    Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
    Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
    Pineo GF; Hull RD
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
    Hull RD
    Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry.
    Chevreul K; Brunn M; Cadier B; Haour G; Eltchaninoff H; Prat A; Leguerrier A; Blanchard D; Fournial G; Iung B; Donzeau-Gouge P; Tribouilloy C; Debrux JL; Pavie A; Gilard M; Gueret P;
    Arch Cardiovasc Dis; 2013 Apr; 106(4):209-19. PubMed ID: 23706367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes.
    Baroletti S; Piovella C; Fanikos J; Labreche M; Lin J; Goldhaber SZ
    Thromb Haemost; 2008 Dec; 100(6):1130-5. PubMed ID: 19132240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital.
    Lee M; Pao D; Hsu T; Sonderskov A
    Can J Clin Pharmacol; 2004; 11(1):e17-27. PubMed ID: 15226523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.